Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
Precision BioSciences, a clinical-stage biotechnology firm, is set to report its Q2 2020 financial results on August 13, 2020. The company's ARCUS® genome editing platform aims to enhance therapeutic safety and efficacy, focusing on CAR T immunotherapy and gene correction therapies for genetic diseases. Additionally, CEO Matt Kane and CMO Chris Heery will represent the company at the William Blair Biotech Focus Conference on August 6 and the BTIG Virtual Biotechnology Conference on August 10. Live presentations will be available on their official website.
Precision BioSciences (Nasdaq: DTIL) announced it will regain full rights to its in vivo chronic hepatitis B virus (HBV) program previously developed in collaboration with Gilead Sciences. The company valued the collaboration, which is set to conclude on September 4, 2020, and anticipates no changes to its cash runway. As of March 31, 2020, cash and cash equivalents stood at $154.2 million, expected to fund operations into mid-2021. ARCUS gene editing has shown promise in targeting HBV, with preclinical data demonstrating significant effectiveness in knocking down HBV genomes.
Precision BioSciences (Nasdaq: DTIL) has initiated a Phase 1/2a clinical trial for its third allogeneic CAR T therapy candidate, PBCAR269A, targeting relapsed/refractory multiple myeloma. The first patient has been dosed, with the trial emphasizing the use of clinical materials produced at the company's in-house facility. PBCAR269A has shown promise in preclinical models, effectively reducing BCMA+ tumor cells without causing graft-versus-host disease. The FDA has granted it Orphan Drug Designation for multiple myeloma treatment.
Precision BioSciences (DTIL), a clinical-stage biotechnology firm, announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 3, 2020, where CEO Matt Kane will speak from 9:30 AM to 9:55 AM ET. Following that, the company will present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, with Kane speaking from 8:50 AM to 9:30 AM ET. Live webcasts can be accessed on the company’s website, with replays available for 30 days post-presentation.
Summary not available.